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Abstract: 2-Phenylamino-6-oxo-9-(4-hydroxybutyl)purine (HBPG) is a thymidine kinase 
inhibitor that prevents encephalitic death in mice caused by herpes simplex virus (HSV) types 1 
and 2, although its potency is somewhat less than that of acyclovir (ACV). The present study was 
undertaken to determine the effect of combinations of HBPG and either ACV, phosphonoformate 
(PFA), or cidofovir (CDF) against HSV encephalitis. BALB/c mice were given ocular infections 
with HSV-1 or HSV-2, and treated twice daily intraperitoneally for five days with HBPG, alone 
or in combination with ACV, PFA, or CDF. Animals were observed daily for up to 30 days, 
and the day of death of each was recorded. All of the combinations showed additivity, and 
the combination of HBPG + ACV appeared to be synergistic, ie, protected more mice against 
HSV-1 encephalitis compared with each drug given alone. Delay of treatment with HBPG for 
up to two days was still effective in preventing HSV-2 encephalitis. The combination of the 
thymidine kinase inhibitor HBPG and the antiherpes drug ACV may have synergistic activity 
against HSV encephalitis. The development of a potent and safe combination therapy for the 
prevention and/or treatment of HSV infection of the central nervous system can improve the 
outcome of this infection in humans.
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Introduction
The major mucocutaneous diseases caused by herpes simplex virus (HSV) in humans 
are well managed by existing antiviral drugs, but neonatal herpes and herpes encephalitis 
are not.1 The drug of choice in the latter diseases is intravenous acyclovir (ACV), and 
an alternative drug for ACV-resistant viruses is foscarnet (phosphonoformate [PFA]), 
but some mortality still occurs and considerable morbidity remains for survivors.
HSV encephalitis is the most common form of fatal encephalitis in the US. Reports 
of prevalance of HSV encephalitis2,3 suggest that it occurs from 1–2 per 100,000 persons 
per year in the US. A detailed survey by the Centers of Disease Control4 for the years 
1988–1997 reported an average of 2,151 hospitalizations per year for confirmed HSV 
encephalitis. (This may be an underestimate, because the causes of 59.5% of 18,680 
hospitalizations for encephalitis were not disclosed.) Herpetic encephalitis results in 
high mortality, and survivors are often severely handicapped.
Recent published estimates of the incidence of neonatal herpes range from one 
per 3,500–5,000 births3 to three per 10,000 births or 1,200 cases per year in the US.5 
Often this results because of massive exposure of the neonate to virus (usually HSV 
type 2) shed in the birth canal. The infected newborn may experience localized skin 
and ocular lesions, viremia, and localized central nervous system lesion development, Drug Design, Development and Therapy 2009:3 290
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usually starting within six days of birth. If infection results 
in disseminated disease, central nervous system (CNS) 
disease occurs in up to 50% of the infants and can result in 
75% mortality. For the survivors of CNS involvement, the 
outcome is bleak, with psychomotor retardation in 50% to 
75% of the survivors.
Intravenous acyclovir (ACV) is the drug of choice for 
therapy of newborns with localized or disseminated HSV 
disease, although vidarabine and phosphonoformate (PFA) 
have also been used. Although these treatments have reduced 
mortality from encephalitis to 15%, only 50% of survivors 
develop normally.3 Unfortunately the overall mortality for 
disseminated neonatal herpes remains very high (40% to 
65%) regardless of present antiviral therapy. Clearly there 
is a need for a superior antiviral drug which enters the CNS 
and inhibits infection and related neurological sequellae.
Recently we reported that an inhibitor/substrate of HSV 
types 1 and 2 (HSV-1, HSV-2) thymidine kinases, viz. 
2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine (HBPG) 
demonstrated potent antiviral activity in experimental mod-
els of HSV reactivation and encephalitis in mice.6 The lack 
of activity of closely related analogs suggests the possibil-
ity that HBPG owes its antiherpetic activity in the animal 
models, at least in part, to its conversion to phosphate forms 
in vivo. We now report the unexpected finding of additivity 
and possible synergism between HBPG and antiherpes 
drugs against HSV encephalitis in mice, most significantly 
with ACV.
Materials and methods
Materials
HBPG was synthesized as described,7 and ACV and PFA were 
purchased from Sigma (St. Louis, MO). Cidofovir (CDF) 
was a gift from Gilead Sciences Inc. (Foster City, CA). The 
McKrae strain of HSV-1 was isolated by Dr. Kaufman (LSU 
Eye Center, New Orleans, LA) and the F strain of HSV-1 and 
G strain of HSV-2 were obtained from the American Type 
Culture Collection (Manassas, VA). All viruses were propa-
gated and titered on Vero cells, and stored frozen until use.
encephalitis models
Six-week-old BALB/c female mice were provided food 
and water ad libitum and were maintained in an AAALAC 
accredited animal care facility.
Ocular infection
Mice were anesthetized by intraperitoneal (IP) injection 
of ketamine (200 mg/kg) and xylazine (20 mg/kg), their 
corneas lightly scratched with a 27 gauge needle, and 1 × 105 
plaque-forming units (PFU) of infectious virus were dropped 
on each cornea.8 The animals were returned to their cages to 
recover from anesthesia.
intranasal infection
Mice were anesthetized as above and infected with 2 × 105 
PFU of infectious virus. Using a sterile pipet tip loaded 
with 10 µL of the virus suspension, the liquid was deposited 
intranasally by gently inserting the pipet tip into the nasal 
opening and expelling the virus.8 The animals were returned 
to their cages to recover from anesthesia.
Drug treatment
Immediately following the infection and recovery from 
anesthesia, groups of 10 animals were given 0.1 mL IP injections 
of suspensions of test compounds in corn oil at the indicated 
dose or corn oil vehicle alone. Treatments were typically contin-
ued twice daily for five days, at 12-hour intervals (at 7 am and 
7 pm). Animals were observed daily for a total of 30 days, and 
the day of death of each animal recorded. Plotting of survival vs 
dose gave the ED50 (the concentration of active compound that 
inhibited plaque formation by 50%) values in Table 1; ED50 is 
the individual dose that protected half of the animals.
statistical analysis
Results of treatment groups were compared to controls for 
significance by the Fisher’s exact test. Mean day of death 
(MDD) was calculated for each treatment group and compared 
to controls for significance by the Mann–Whitney U test.
Plaque reduction assays
Virus stocks were diluted in cold Dulbecco’s modified 
Eagle’s medium (DMEM) containing 2% fetal bovine serum 
(FBS), and six-well trays containing confluent monolayers of 
Vero cells were infected with 200 µL/well of virus (to yield 
150–250 PFU/well). Test compounds were dissolved in 
Table 1 eD50s of single drugs vs hsV encephalitis in micea
Drug  ED50, mg/kgb
HSV-1 HSV-2
AcV 82 90
PFA 200 300
cidofovir 3.2 2.4
hBPG 150 103
Notes: aOcular infection with hsV-1 or hsV-2. bTreatment begun immediately after 
infection and continued twice daily (every 12 hours) IP for five days, in corn oil.
Abbreviations:   AcV, acyclovir; hBPG, 2-phenylamino-6-oxo-9-(4-hydroxybutyl)purine; 
hsV, herpes simplex virus; iP intraperitoneal; PFA, phosphonoformate.Drug Design, Development and Therapy 2009:3 291
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dimethyl sulfoxide (DMSO) at 10 mg/mL, and diluted in 
overlay medium (DMEM containing 2% FBS and 0.25% 
methylcellulose) singly or in combination. After one hour of 
adsorption at 37°C, the viral inoculum was removed, and cells 
were overlaid with 2.5 mL of medium. Each test compound 
concentration or combination was tested in duplicate wells. 
Plates were incubated at 37°C for 36–48 hours, and plaques 
were counted. The percent plaque reduction was calculated 
based on the number of plaques obtained in the absence of 
drugs. Antiviral activity is expressed as EC50.
Results
Various routes of infection have been used to establish HSV 
encephalitis in mice, including intranasal,9 intracerebral 
and IP,10,11 and intracutaneous.12 We used primarily ocular 
infection (see below) for comparison of drug–drug combina-
tion efficacy. Mean days of death after infection (MDD) in 
untreated animals were usually 9–10 with HSV-1 and 11–12 
with HSV-2 infections. For comparison, in one experiment 
we used intranasal infection in which the MDDs for HSV-1 
and HSV-2 were 9.1 and 9.9 days, respectively.
effect of single drugs on hsV encephalitis
The standard treatment regimen of twice daily IP injections 
of compounds in corn oil suspensions for five days beginning 
immediately after recovery from anesthesia was used to 
compare efficacy of individual drugs. The antiherpes drugs 
PFA, ACV, and CDF and the experimental compound HBPG 
protected animals from HSV-1 and/or HSV-2 encephalitic 
death following infection by the ocular route in a dose depen-
dent manner. The ED50 values (Table 1) show that CDF is 
by far the most effective drug, and that ACV and PFA have 
potencies within about twofold of each other. These results 
are consistent with reported activity of the drugs on HSV 
encephalitis in mice (see DeClercq and Holý).12 HBPG6 was 
effective against both HSV-1 and HSV-2 encephalitis, and 
was intermediate in potency compared with ACV and PFA. 
Infections with HSV-1 or HSV-2 by the intranasal route were 
equiresponsive to the same regimens of HBPG and CDF 
(data not shown).
Delay of treatment
To compare the ability of HBPG to prevent an infection and to 
treat an established infection, the efficacy of the typical regi-
men (IP twice daily for five days) against HSV-2 encephalitis 
was measured after initiating treatment one, two, and three 
days after infection. The results, depicted graphically in 
Figure 1, show that gradual loss of HBPG efficacy occurred, 
but that substantial protection remained even when treatment 
began two full days after infection.
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Figure 1 Efficacy of HBPG against HSV-2 encephalitis in mice after various delays in starting dosing post-infection. HBPG was given twice daily for five days.
Notes: For reduction of mortality, P  0.05 at one and two days postinfection (Fisher’s exact test). For MDD, P  0.05 at one and two days postinfection (Mann–Whitney 
U test).
Abbreviations: hBPG, 2-phenylamino-6-oxo-9-(4-hydroxybutyl)purine; hsV, herpes simplex virus; MDD, mean day of death.Drug Design, Development and Therapy 2009:3 292
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effect of drug combinations on hsV 
encephalitis
Combinations of HBPG with the standard antiherpes 
drugs increased survival of mice with HSV-1 and HSV-2 
encephalitis over the expected results for simple additivity 
(Table 2). Using the ED50 values for each drug from Table 1 
and the assumption of parallel dose-response curves, addi-
tion of the fractions of the ED50 of each was used to predict 
results of dosing of the combinations, assuming simple 
additivity of responses, ie, essentially a limited isobolo-
gram approach.13 Table 3 summarizes the results for several 
combinations. The results strongly suggest that HBPG and 
ACV are synergistic in their effect on HSV-1 encephalitis. 
For example, the expected survival of HSV-1-infected ani-
mals given 100 mg/kg HBPG + 50 mg/kg ACV was 64%, 
but the combination gave 100% survival. HBPG and CDF 
also appeared synergistic against HSV-1, but not against 
HSV-2 encephalitis. No conclusions can be drawn about the 
combination of HBPG and PFA. Although suggestive, the 
data are insufficient to prove whether any combinations are 
synergistic or additive.
effect of the combination hBPG + AcV 
on hsV-1 growth in proliferating cells
The EC50 of ACV for plaque reduction in HSV-1 infected 
Vero cells (see Materials and methods) was 2.2 µg/mL, 
and that of HBPG was 100 µg/mL. When 10 µg/mL of 
HBPG was present the apparent EC50 of ACV increased to 
7.5 µg/mL, suggesting antagonism of the antiviral effect. 
This result is consistent with observations for selective 
herpesvirus thymidine kinase inhibitors, which antagonize 
the activity of ACV in cell cultures (reviewed by Spadari and 
Wright).14 In contrast, the EC50 of PFA for plaque reduction 
in HSV-1 infected Vero cells was 20 µg/mL in the absence 
and 18 µg/mL in the presence of 10 µg/mL HBPG. PFA is a 
pyrophosphate analog that does not require activation by thy-
midine kinase. Thus the apparent synergism between ACV 
and HBPG against HSV encephalitis involves a completely 
different mechanism than inhibition of thymidine kinase.
Discussion
The thymidine kinase inhibitor/substrate HBPG was effective 
in protecting mice from death caused by infection with HSV-1 
and HSV-2. The compound is intermediate in potency between 
ACV and PFA, the current drugs used to treat human cases of 
herpes encephalitis and neonatal herpes. The basis for activity 
of HBPG was first thought to involve inhibition of thymidine 
kinase in the CNS, given that neurons already contain low 
levels of precursors of DNA synthesis. Because HBPG is an 
efficient substrate for the viral TK6 it is also possible that the 
monophosphate or triphosphate of the compound is the active 
form. However, both the monophosphate and triphosphate of 
HBPG were weak inhibitors of the viral (HSV-1) DNA poly-
merase (Focher, unpublished observations) that is the target of 
nucleoside analogs as their triphosphates. If direct inhibition 
of thymidine kinase was the mechanism of antiencephalitic 
activity of HBPG, the compound would be expected to antago-
nize the activity of ACV. Indeed, this is just what is found in 
plaque reduction assays of HSV infected proliferating cells 
(see above and Spadari and Wright).14 HBPG, however, was 
Table 2 effect of drug combinations on hsV encephalitis in micea
HBPG dose, mg/kg Drug, dose, mg/kg HSV-1 HSV-2
Survivors/treatedb 
(P value)d
MDD  
(P value)e
Survivors/treatedb 
(P value)d
MDD  
(p value)e
0c 0c 0/10 9.1 0/10 13.7
25 PFA, 50 nt nt 1/10 (P = 0.5) 14.3 (p = 0.14)
50 nt nt 9/20 (P = 0.012) 13.3 (p = 0.4)
100 ” nt nt 8/10 (P  0.001) 15 (p  0.05)
25 AcV, 50 5/10 (P = 0.016) 11.2 (P = 0.19) nt nt
50 ” 8/10 (P  0.001) 14 (P = 0.02) nt nt
100 ” 10/10 (P  0.001) na nt nt
25 cidofovir, 2.5 7/10 (P = 0.002) 10.3 (P  0.05) 6/10 (P = 0.005) 12 (p  0.05)
50 ” 9/10 (P  0.001) 10 (P  0.05) 10/10 (P  0.001) –
100 ” 10/10 (P  0.001) – 10/10 (P  0.001) –
Notes: aAnimals were infected ocularly with HSV-1 or HSV-2 and treated IP twice daily (every 12 hours) for five days with suspensions of drug combinations in corn oil or 
vehicle (corn oil) alone; bat 30 days; cvehicle alone; dFisher’s exact test; eMann–Whitney U test.
Abbreviations: AcV, acyclovir; hBPG, 2-phenylamino-6-oxo-9-(4-hydroxybutyl)purine; hsV, herpes simplex virus; iP intraperitoneal; nt, not tested; PFA, phosphonoformate.Drug Design, Development and Therapy 2009:3 293
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found unexpectedly to be additive or even synergistic with 
ACV against HSV-1 encephalitis (Tables 2 and 3), suggest-
ing a mechanism of interaction in vivo that is different from 
simple antagonism expected of competitors for TK. Several 
studies have explored antiherpes combinations active against 
different viral targets. For example, a ribonucleotide reductase 
inhibitor potentiated activity of ACV,15 and docosanol was 
synergistic with various nucleoside analogs.16 These findings 
are consistent with the synergism observed when antiviral 
activities are directed against independent targets.
The treatment of HSV infection in the CNS requires that 
the drug reach this tissue at an effective concentration and 
in a timely manner. HSV infection of an epithelial surface, 
for example the nasal passages or the cornea, results in entry 
of the virus into the peripheral nervous system in two days 
and the CNS in three days. Exactly how many viral particles 
reach the CNS initially or how many rounds of viral repli-
cation are necessary to produce encephalitis is not known. 
Temporal studies with HBPG showed that 7 of 10 mice were 
protected from HSV-2 encephalitic death when treatment 
was begun two days after infection (Figure 1). In contrast, 
little efficacy of ACV was observed after a 24-hour17 or 
longer12 delay of treatment, and PFA showed a gradual loss 
of efficacy over a three day period postinfection.10 Only the 
phosphonate compound CDF prevented lethality of herpes 
encephalitis when treatment was delayed until four days 
postinfection.12
The observation that HBPG exerts a protective effect 
two days after infection indicates that the drug penetrates 
the CNS in a therapeutically effective concentration and may 
reduce viral replication both before and after the develop-
ment of encephalitis. Questions remaining to be answered 
include: Exactly how many viral particles reach the CNS? 
How much replication must occur to induce encephalitis? 
What is the concentration of HBPG in the CNS using the 
reported dose schedule? Is the combined drug therapy acting 
primarily outside the CNS? Is a significant component of the 
protection mediated in the CNS? Based on the disastrous 
consequences of CNS infection by HSV in encephalitis 
and neonates and our encouraging results indicating that 
mice can be protected against CNS infection by HBPG and 
a combination of HBPG and ACV, we believe that further 
study is warranted.
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